The Virtual CVOT Summit 2024 will start on 5 December at 15:30 CET.The livestream will start today at 15:30 CET.Welcome and Introduction15:30 – 15:40 CETOliver Schnell (Munich, Germany)Update on the treatment of heart failure - new approaches, new outcomes15:40 – 15:55 Mikhail Kosiborod (Kansas City, US)Chronic kidney disease: Cornerstones of today´s treatment and opportunities for the future15:55 – 16:10 Beatriz Fernández-Fernández (Madrid, Spain)The next decade in the treatment of obesity16:10 - 16:25Barbara McGowan (London, UK)Organ Cross-Talk and Person-Centered Management of Obesity, CKD, Lipid Disorders, and Diabetes16:25 - 16:45Dirk Müller-Wieland (Aachen, Germany)Microplastics and nanoplastics (MNPs): An emerging risk factor for cardiovascular disease16:45 - 17:00Antonio Ceriello (Milan, Italy)Panel Discussion17:00 – 17:15Break17:15 – 17:30 CETThe Taskforce of the Guideline Workshop: Aims and outcomes17:30 – 17:45 Oliver Schnell (Munich, Germany)Towards standardization of patient reported outcomes (PROs)17:45 – 18:00Katharine Barnard-Kelly (Hampshire, UK)Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases18:00 – 18:15Helena Rodbard (Rockville, USA)Network meta-analyses and clinical guidelines: what is missing for a precision medicine approach 18:15 – 18:30Francesco Giorgino (Bari, Italy)Discussion18:30 – 18:45Break18:45 – 19:00 CETWelcome and introduction 19:00 – 19:03Sarah Jarvis (London, UK)Why does connecting the dots matter in CRM diseases?19:03 - 19:13Nikolaus Marx (Aachen, Germany)Connecting the dots in CRM disease: how do we work together?19:13 – 19:23Sarah Jarvis (London, UK)Connecting the dots in understanding CRM disease: does aldosterone have a role?19:23 – 19:33Per-Henrik Groop (Helsinki, Finland)Panel discussion: Connecting the dots in multidisciplinary care19:33 - 19:58Closing remarks/final thoughts19:58 - 20:00Sarah Jarvis (London, UK)OP 1: Micro- and Macroangiopathy Related to Diabetes: Beyond HbA1c, Should We Rely on New Glucose Metrics?Bruno Guerci (Nancy, France)OP 2: The Impairment of Myocardial Structure in Patients with Type 2 Diabetes Mellitus without Cardiovascular DiseaseIvanna Zubovych (Kyiv, Ukraine)OP 3: Characterizing the Healthcare Resource Use and Costs for Patients Aged 65-89 Years with Laboratory Evidence of CKD With and Without a Recorded DiagnosisJieling Chen (Gaithersburg, USA)OP 4: Improvement of Health-Related Quality of Life after Bariatric Surgery in Patients with Severe Obesity and Type 2 DiabetesTamar Shervashidze (Tbilisi, Georgia)Closing of Day 120:45 CETOliver Schnell (Munich, Germany)The Virtual CVOT Summit 2024 continues tomorrow, Friday, 6 December, at 08:30 CET. We look forward to your participation!The Virtual CVOT Summit 2024 continues tomorrow, Friday, 6 December, at 08:30 CET. We look forward to your participation!The livestream will start today at 08:30 CET.Early detection of Type 1 Diabetes - risk evaluation, markers and early diagnosis programs08:30 – 08:45Thomas Danne (Lisbon, Portugal)Treatment strategies for delaying the onset of Type 1 Diabetes08:45 – 09:00Colin M. Dayan (Cardiff, UK)Future directions in the treatment of CKD in Type 1 Diabetes 09:00 – 09:15 Hiddo Heerspink (Groningen, Netherlands)Discussion09:15 – 09:30Continuous glucose monitoring in Type 2 Diabetes09:30 – 09:45 Stefano del Prato (Pisa, Italy)CGM and cardiovascular perspectives09:45 – 10:00Ulf Landmesser (Berlin, Germany)CGM, hypoglycemia and risk prediction10:00 – 10:15Lutz Heinemann (San Diego, US)Automated Insulin delivery (AID), physical activity and exercise in Type 1 Diabetes10:15 – 10:30Othmar Moser (Bayreuth, Germany)Discussion10:30 - 10:45Break10:45 – 11:00 CETUACR and eGFR: barriers of implementation 11:00 - 11:15Elke Schäffner (Berlin, Germany)KDIGO guidelines 2024: consistence with ESC?11:15 – 11:30Michel Jadoul (Brussels, Belgium)REVOLUTIONizing heart failure diagnosis11:30 – 11:45Lisa Anderson (London, UK)Discussion11:45 - 12:00Cardiac autonomic neuropathy: current experimental and clinical practice considerations12:00 – 12:10Alin Stirban (Birkenwerder, Germany)Mitochondrial metabolomics and the diabetic heart12:10 – 12:20 Eberhard Standl (Munich, Germany)Discussion12:20 – 12:30Cardiovascular Risk evaluation in primary care12:30 – 12:45Naresh Kanumilli (Manchester, UK)Interconnectedness of Heart, Kidney and Metabolism – Perspectives of PCPs12:45 - 13:00Xavier Cos (Barcelona, Spain)Empowering diabetes self-management: the path to success13:00 - 13:15Tatjana Milenkovic (Skopje, Macedonia)Discussion13:15 – 13:30Break13:30 - 14:00 CETObesity as a therapeutic target in heart failure therapy14:00 – 14:15Luc van Gaal (Antwerp, Belgium)GIP/GLP-1 receptor agonists – a new dawn in sleep apnea therapy?14:15 – 14:30 Igor Harsch (Saalfeld, Germany)Discussion14:30 - 14:45On the Path to Precision Nutrition in Cardiometabolic Diseases14:45 - 15:00Andreas Pfeiffer (Potsdam, Germany)Navigating Nutrition under Incretin-Based Therapies15:00 - 15:15Jaime Almandoz (Texas, USA)Discussion15:15 - 15:30Diagnosis and Treatment of MASLD: Current State of the Art15:30 - 15:45Wendy Spearman (Cape Town, South Africa)The liver – a new target for incretin therapies?15:45 - 16:00 Frank Tacke (Berlin, Germany)Discussion16:00 - 16:15Break16:15 - 16:30 CETIndustry’s perspective - Panel Discussion16:30 - 17:30 CETOliver Schnell (Munich, Germany)OP 5: Aldosterone Synthase Inhibitor Vicadrostat (BI 690517) ± Empagliflozin in a CKD Phase II Trial: Effects on Albuminuria and SBP in Patients with/without T2DPeter Rossing (Copenhagen, Denmark)OP 6: Endothelial Dysfunction and Cardiovascular Pathology in Patients with Metabolic Dysfunction-Associated Steatotic Liver DiseaseKateryna Pivtorak (Vinnytsia, Ukraine)OP 7: Consistency in Glucose Monitoring, Consistency in Care: Standardizing CGM Evaluation for Better Patient OutcomesStefan Pleus (Ulm, Germany)OP 8: Age is No Barrier to Diabetes Technology: Improvements in Glycemia in Older People with Type 2 Diabetes Mirror Engagement Levels with the OneTouch Reveal® Mobile Diabetes Management AppElizabeth Holt (Malvern, PA, USA)Abstract Award and Closing18:15 – 18:30 CET Oliver Schnell (Munich, Germany) Thank you for your attendance and contribution to the Virtual CVOT Summit 2024.
See you next year for the 11th CVOT Summit on 20 - 21 November 2025.Thank you for your attendance and contribution to the Virtual CVOT Summit 2024.
See you next year for the 11th CVOT Summit on 20 - 21 November 2025. We will be right back.We are currently having some technical issues. We will be right back.The page is automatically updated.The next program item is loaded.
Join us at the Virtual CVOT Summit 2025
The upcoming CVOT Summit 2025 will take place as a virtual event from 20 to 21 November 2025. As in our previous CVOT Summits, we look forward to welcoming a broad virtual audience of cardiologists, nephrologists, endocrinologists and general practionioners from all around the world.
Following our tradition, the Virtual CVOT Summit 2025 will cover the latest developments and news in the various areas of research and clinical practice related to cardiovascular, kidney and metabolic outcomes. Join us for an update on the latest outcome trials, scientific studies, clinical guidelines and practical recommendations presented by global highly distinguished professionals and experts. We look forward to meeting you again at this year’s Virtual CVOT Summit from 20 to 21 November 2025!
